After Data Miss in Lead Cancer Indication, Replimune Maps Pa

After Data Miss in Lead Cancer Indication, Replimune Maps Path for Oncolytic Virus

Replimune’s lead therapeutic candidate did not meet the two main goals of a study intended to support an FDA submission in cutaneous squamous cell carcinoma. But Replimune’s therapy, an oncolytic virus, has better data in melanoma, and the company plans a 2024 FDA submission in this skin cancer.

Related Keywords

Massachusetts , United States , Jonathan Chang , Regeneron Pharmaceuticals , Bristol Myers Squibb , Leerink Partners , Weight Loss , Obesity , Verweight , Diabetes , Medical Devices , Startups , Healthcare Innovation , Medcity News , San Francisco , Life Sciences , Accelerator , Rock Health , Startup Advice , Startup Funding , Patient Monitoring System , Otion Sensors , Dc , Healthcare It , Washington , Foodborne Pathogens , Iagnostics Company , Iagnostic Platforms , Minimally Invasive Surgery , Aser Surgery , Cambridge , Dealflow , Hospitals , Wellpoint , Ealthways , Ealth And Wellness , Mployee Wellness Programs , Investing , Wellness , Medtronic , Hanghai Innovation Center , China , R D , Mdt , Minneapolis , Minnesota , Publics , Twin Cities , Ulcerative Colitis , Abbott Labs , Humira , Doctors , Pharmaceuticals , Skin Disorders , D Anderson Cancer Center , Cancer , Texas , Renal Denervation , St Jude Medical , Stj , Emr , Hr , Electronic Health Records , Electronic Medical Records , Certified Emr , Ehr , Advanced Cellular Technology , Amyotrophic Lateral Sclerosis , Embryonic Stem Cells , Geron Corporation , Lou Gehrigs Disease , Macular Degeneration , Regenerative Medicine , Spinal Cord Damage , Value Based Healthcare System , Obamacare , Ee For Service Model , California , Cleveland , Health Insurance , Insurance , Ohio , Pennsylvania , Politics , Cancer Treatment Options Library , Aetna , Pet , Aet , Health It , Phi , Philadelphia , Biopharma Nl , Dancer , Clinical Trials , Melanoma , Oncolytic Virus , Replimune , Skin Cancer , ,

© 2025 Vimarsana